Treatment of Bullous Pemphigoid

Initial Treatment

The British Association of Dermatologists recommends superpotent topical corticosteroids, such as clobetasol propionate 0.05%, as the first-line treatment for bullous pemphigoid, providing superior disease control with lower mortality compared to systemic corticosteroids 1, 2
For localized or limited disease, apply clobetasol propionate 10-20 g daily to lesional skin only, achieving complete healing in all patients within 4-17 days 1, 3
If disease control is not achieved within 1-3 weeks, increase the dose to 40 g daily 1
For mild disease, apply clobetasol propionate 20 g daily over the entire body except the face 1, 2
For extensive or moderate-to-severe disease, first-line treatment is clobetasol propionate 30-40 g daily applied to the entire body surface 1, 3

Begin dose reduction 15 days after achieving disease control, gradually tapering topical steroids over 4 months 1, 2
After 4 months, reduce to 10 g clobetasol propionate once weekly, applied preferentially to previously affected areas 1, 2
Continue maintenance for 8 additional months, aiming to stop treatment completely 4-12 months after initiation 1, 2

Oral prednisone 0.5 mg/kg daily is effective for mild disease, with doses <0.5 mg/kg being ineffective 1, 4
Implement osteoporosis prevention measures at the outset of systemic corticosteroid treatment 4, 2
Doxycycline 200 mg daily, tetracycline 500-2000 mg daily, or minocycline 100-200 mg daily, often combined with nicotinamide 500-2500 mg daily, are alternative options for patients with comorbidities 4, 3, 2

Rituximab (anti-CD20 antibody) 375 mg/m² weekly for 4 weeks is the most studied biologic for refractory bullous pemphigoid, achieving satisfactory response in 78% and complete clearance in 55% of recalcitrant cases 5
Consider mycophenolate mofetil 0.5-1 g twice daily or intravenous immunoglobulin (IVIg) for cases unresponsive to all standard therapies 3

Follow-up visits every 2 weeks for the first 3 months, then monthly for the next 3 months, then every 2 months 2
Baseline and regular monitoring: complete blood count, liver function tests, glucose, renal function, blood pressure 3, 2
Anti-BP180 IgG by ELISA at days 0, 60, and 150, with values >27 U/mL indicating increased relapse risk 2, 6